| 0.4953 0.005 (1.08%) | 10-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.6 | 1-year : | 0.64 |
| Resists | First : | 0.51 | Second : | 0.55 |
| Pivot price | 0.49  |
|||
| Supports | First : | 0.44 | Second : | 0.37 |
| MAs | MA(5) : | 0.49 |
MA(20) : | 0.49 |
| MA(100) : | 0.53 |
MA(250) : | 3.77 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 46.7 |
D(3) : | 43 |
| RSI | RSI(14): 49.3 |
|||
| 52-week | High : | 15.39 | Low : | 0.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RVPH ] has closed below upper band by 47.2%. Bollinger Bands are 75.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 131 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.51 - 0.51 | 0.51 - 0.52 |
| Low: | 0.45 - 0.46 | 0.46 - 0.46 |
| Close: | 0.49 - 0.5 | 0.5 - 0.5 |
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Sun, 11 Oct 2026
Reviva Pharmaceuticals Holdings (OTCPK:RVPH) - Stock Analysis - Simply Wall Street
Tue, 22 Sep 2026
Two drug candidates will be presented Sept. 29 by Reviva's CEO - Stock Titan
Wed, 12 Aug 2026
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
Mon, 27 Jul 2026
REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. Market Sentiment - Benzinga España
Fri, 10 Jul 2026
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) — Files Form 25 to remove Common Stock from Nasdaq listing - Stock Titan
Fri, 26 Jun 2026
RVPH Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 7.7 (%) |
| Held by Institutions | 8.2 (%) |
| Shares Short | 1,870 (K) |
| Shares Short P.Month | 1,830 (K) |
| EPS | -1.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.5 % |
| Return on Equity (ttm) | -176.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.35 |
| PEG Ratio | 0 |
| Price to Book value | 0.42 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|